Daily Archives: May 1, 2023
THE GUT MICROBIOME REGULATES EFFICACY OF SULFASALAZINE THERAPY FOR SPONDYLOARTHRITIS IN INFLAMMATORY BOWEL DISEASE
Joint inflammation, or spondyloarthritis (SpA), is the most common extra-intestinal manifestation of inflammatory bowel disease (IBD), but the specific role for therapies targeting SpA is not well defined. One of the earliest medications used for the t… Continue reading
ACONITATE DECARBOXYLASE 1 IS A KEY REGULATOR OF COLITIS
Aconitate decarboxylase 1 (ACOD1; also known as IRG1) is highly expressed in activated macrophages and converts cis-aconitate to itaconate, which contributes to the antimicrobial activity of macrophages. The role of ACOD1 in intestinal inflammation rem… Continue reading
PATHOPHYSIOLOGY OF IRRITABLE BOWEL SYNDROME IN PATIENTS WITH QUIESCENT INFLAMMATORY BOWEL DISEASE
The presence of symptoms compatible with irritable bowel syndrome (IBS) in patients with inflammatory bowel disease (IBD) in remission is very common, affecting approximately one third of this population, with a negative impact on quality of life. It’s… Continue reading
A NEW MODEL TO STUDY INTESTINAL FIBROSIS USING IPSC-DERIVED HUMAN EPITHELIAL AND MESENCHYMAL CELLS FROM CROHN’S DISEASE PATIENTS
Intestinal fibrosis is a serious complication of Crohn’s disease (CD) and is caused by the excess deposition of extracellular matrix protein. There are no therapies to prevent or treat this and surgical intervention remains the only treatment option. N… Continue reading
BUTYRATE-INDUCED MITOCHONDRIAL FUNCTION IMPROVES BARRIER FUNCTION IN INFLAMMATORY BOWEL DISEASE (IBD)
Short-chain fatty acids (SCFAs), end-product of gut microbial metabolism, play an important role in colonic homeostasis. Butyrate is a prime SCFA that fuels intestinal epithelial cells (IECs). However, this energy source is deficient in inflammatory bo… Continue reading
THE EFFECTS OF BIOLOGIC AND SMALL MOLECULE INHIBITOR THERAPY ON THE MUCOSAL IMMUNE SYSTEM IN ULCERATIVE COLITIS
Ulcerative colitis (UC) is a subtype of inflammatory bowel disease (IBD) that causes relapsing and remitting inflammation in the colon and rectum. Numerous treatment options are available for patients with UC including biologics and small molecule inhi… Continue reading
THE RELATIONSHIP BETWEEN SELF-REPORTED SLEEP, WRIST ACTIGRAPHY, AND SYMPTOMS AMONG ADULTS WITH INFLAMMATORY BOWEL DISEASE (IBD)
Recently, there has been a growing recognition of the bidirectional link between sleep and inflammation. Several studies have reported the prevalence of sleep disturbances in those with Inflammatory Bowel Disease (IBD) and found poor sleep has the pote… Continue reading
SOCIALLY VULNERABLE PATIENTS WITH INFLAMMATORY BOWEL DISEASE ARE AT INCREASED RISK FOR VACCINE PREVENTABLE ILLNESS
Inflammatory bowel disease (IBD) affects patients across diverse ethnic, minority, cultural, and socioeconomic backgrounds; however, the relationship between these social determinants of health (SDOH) and IBD outcomes is not well-studied. SDOH have a k… Continue reading
PRELIMINARY EVIDENCE FOR A RELATIONSHIP BETWEEN HEART RATE VARIABILITY AND FATIGUE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD)
Heart Rate Variability (HRV), the variation in time between each heartbeat, is a proxy for vagus nerve function and validated indicator of cardiovascular health. Lower HRV is associated with increased risk of cardiac events and greater vulnerability to… Continue reading
MULTIPLE ENVIRONMENTAL AND SOCIAL DETERMINANTS OF HEALTH FACTORS WERE NOT ASSOCIATED WITH THE GASTROINTESTINAL SYMPTOMATIC BURDEN OF ULCERATIVE COLITIS WITH MUCOSAL HEALING
In a biopsychosocial interdisciplinary model, complex interactions between the hosts (individuals/patients), disease (e.g., ulcerative colitis [UC]), and environment (e.g., social determinants of health [SDOH]) may all contribute to the disease burden…. Continue reading